Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity.

Blood - 1 May 2002

Bollard Catherine M, Rössig Claudia, Calonge M Julia, Huls M Helen, Wagner Hans-Joachim, Massague Joan, Brenner Malcolm K, Heslop Helen E, Rooney Cliona M

Abstract excerpt

Transforming growth factor beta (TGF-beta), a pleiotropic cytokine that regulates cell growth and differentiation, is secreted by many human tumors and markedly inhibits tumor-specific cellular immunity. Tumors can avoid the differentiating and apoptotic effects of TGF-beta by expressing a nonfun...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adjuvants, Immunologic
Share to Herpesvirus 4, Human
Share to Hodgkin Disease

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Receptor, Transforming Growth Factor-beta Type II

Share to Receptors, Transforming Growth Factor beta

Share to Smad2 Protein

Share to T-Lymphocytes, Cytotoxic

Share to Transduction, Genetic

Source

Identifiers

PMID: 11964281
DOI: 10.1182/blood.v99.9.3179

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-11964281-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity.PMID 11964281Read ↗

Engineering Cancer Antigen-Specific T Cells to Overcome the Immunosuppressive Effects of TGF-βSemantic proximity Read ↗

Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma.Semantic proximity Read ↗

TGF-β directly targets cytotoxic T cell functions during tumor evasion of immune surveillanceSemantic proximity Read ↗

Chemotherapy rescues tumor-driven aberrant CD4+ T-cell differentiation and restores an activated polyfunctional helper phenotype.Semantic proximity Read ↗

Adoptive T‐cell therapy for cancer: The era of engineered T cellsSemantic proximity Read ↗

Cytotoxic immunotherapy strategies for cancer: Mechanisms and clinical developmentSemantic proximity Read ↗

TGF-Beta: a Master Switch in Tumor ImmunitySemantic proximity Read ↗

Novel Approaches to Enhance the Specificity and Safety of Engineered T CellsSemantic proximity Read ↗

Genetic Modification of Cytokine Signaling to Enhance Efficacy of CAR T Cell Therapy in Solid Tumors.Semantic proximity Read ↗

CAR Triggered Release of Type-1 Interferon Limits CAR T-Cell Activities by an Artificial Negative Autocrine LoopSemantic proximity Read ↗

Suicide Gene Therapy to Increase the Safety of Chimeric Antigen Receptor-Redirected T LymphocytesSemantic proximity Read ↗

PD-1 and TIGIT downregulation distinctly affect the effector and early memory phenotypes of CD19-targeting CAR T cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.